Uniphar plc (AIM:UPR)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 934.96M |
| Revenue (ttm) | 2.68B |
| Net Income (ttm) | 44.57M |
| Shares Out | n/a |
| EPS (ttm) | 0.17 |
| PE Ratio | 20.98 |
| Forward PE | 15.92 |
| Dividend | 0.02 (0.01%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | 80,859 |
| Average Volume | 363,278 |
| Open | 346.00 |
| Previous Close | 349.00 |
| Day's Range | 346.00 - 361.00 |
| 52-Week Range | 232.00 - 368.00 |
| Beta | n/a |
| RSI | 56.82 |
| Earnings Date | Jun 2, 2026 |
About Uniphar
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with acces... [Read more]
Financial Performance
In 2025, Uniphar's revenue was 3.07 billion, an increase of 10.98% compared to the previous year's 2.77 billion. Earnings were 51.09 million, a decrease of -20.43%.
Financial numbers in EURNews
Competition regulator ‘calls-in’ Uniphar acquisition for review
The Competition and Consumer Protection Commission (CCPC) has "called in” the acquisition of TouchStore Limited by healthcare services provider, Uniphar plc for review.
Healthcare group Uniphar reports revenue topping €3bn last year
Healthcare services group Uniphar has reportedwhat it called a strong set of full-year results, with earnings up sharply and revenue topping the €3bn mark.
Uniphar Earnings Call Transcript: H2 2025
Strong organic growth across all divisions drove a 21% EPS increase and 6% EBITDA growth in 2025, supported by major infrastructure investments and disciplined capital allocation. The group remains confident in achieving its EUR 200 million EBITDA target by 2028.
Uniphar PLC (DUB:UPR) Q4 2025 Earnings Report Preview: What to Look For
Uniphar PLC (DUB:UPR) Q4 2025 Earnings Report Preview: What to Look For
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar Agreement
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar Agreement
Uniphar sees profits rise to 38m as growth accelerates
Operating profits at stock market-listed healthcare services firm Uniphar rose 5.6pc to 38.5m in the first half of the year.
Uniphar Earnings Call Transcript: H1 2025
Strong H1 2025 results with 8% organic gross profit growth and 21% EPS increase, driven by all divisions. Strategic investments in infrastructure and technology are expected to support medium-term EBITDA growth, with a €200m target by 2028.
Uniphar PLC (DUB:UPR) Q2 2025 Earnings Report Preview: What To Look For
Uniphar PLC (DUB:UPR) Q2 2025 Earnings Report Preview: What To Look For
The week ahead in business: Unemployment data, flash estimate on inflation and a host of trading updates
September is here and it is straight down to business with results and trading updates due from Kainos on Monday, Uniphar on Tuesday, Cairn Homes on Wednesday and Grafton Group.
Uniphar flags profit growth for first half of the year
Irish healthcare group Uniphar says the business achieved double-digit adjusted earnings per share growth in the first half of 2025, with 8pc organic gross profit growth and lower finance costs.
Uniphar agrees to undertakings pending injunction hearing over alleged breach of agreement
Dublin-based Thera seeks orders preventing Uniphar from blocking its trading account
Pharmacy brokerage Thera claims Uniphar breaching agreement in takeover bid
A pharmacy brokerage business has claimed in the High Court that pharma giant Uniphar is breaching an agreement in an attempted takeover bid and abusing its dominant position in the market.
Pharmacy broker claims Uniphar breaching agreement in attempted takeover
Company is seeking orders preventing blocking of trading account
Shares in Uniphar up more than 6pc after results
Shares in healthcare service company Uniphar are up more than 6pc after it announced bigger than expected profits and revenue for last year.
Uniphar Earnings Call Transcript: H2 2024
Strong 2024 results with 9.6% gross profit growth and 12% EPS increase, driven by all divisions. Strategic investments and disciplined capital allocation support a €200 million EBITDA target by 2028, with robust organic growth and market share gains in Pharma and MedTech.
The week ahead in business: Bank of Ireland, Uniphar and Glanbia to announce results
Bank of Ireland will announce its full-year results for 2024 today.
Uniphar reports 8pc increase in profits last year
Healthcare service company Uniphar saw an 8pc growth in profits over the last financial year.
Uniphar Earnings Call Transcript: H1 2024
Revenue and gross profit both grew 10% year-over-year, with Pharma leading at 21% gross profit growth. EBITDA rose 6%, leverage improved, and strong organic growth was achieved across all divisions. The group remains confident in its ambitious €200m EBITDA target.
Uniphar reports increase in profits and revenues in first half of 2024
Irish healthcare services business Uniphar reported a rise in profits in the first six months of the year.
Healthcare services group Uniphar reports strong trading momentum in first half of 2024
Irish healthcare services business Uniphar has reported organic gross profit growth of around 7pc in the first six months of the year.
Half Year 2022 Uniphar PLC Earnings Call Transcript
Half Year 2022 Uniphar PLC Earnings Call Transcript
Full Year 2021 Uniphar PLC Earnings Call Transcript
Full Year 2021 Uniphar PLC Earnings Call Transcript
Full Year 2020 Uniphar PLC Earnings Call Transcript
Full Year 2020 Uniphar PLC Earnings Call Transcript
Uniphar sets ambitious new goals for future growth
Uniphar carries 2023 momentum into the new year, setting itself an ambitious mid-term earnings target of EUR200m.